Impact of Interferon-Based Treatment on Quality of Life and Work Related Productivity from the Korean Cohort in the MOSAIC Study

( Sang Hoon Ahn ),( Won Hyeok Choe ),( Yoon Jun Kim ),( Jeong Heo ),( Dorota Latarska-smuga ),( Jiho Kang ),( Seung Woon Paik ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1

Aims: Chronic Hepatitis C Virus (HCV) infection increases the risk for progressive liver disease, hepatocellular carcinoma and negatively impacts the patient’s quality of life. HCV treatment is evolving with direct acting antivirals but IFN based therapy has been the standard of care for many years and remains available in some countries. The MOSAIC study aims to characterize patients with chronic HCV infection and assess the impact of IFN-containing treatment on health-related quality of life, work related productivity and health care utilization. Methods: MOSAIC is an international prospective multicenter observational study that has been conducted in 20 countries. Consecutive patients with chronic HCV infection were enrolled and those who initiated an IFN based regimen were prospectively followed for 48 weeks. We report results from the Korean cohort Results: 100 patients were enrolled: 86 were treatment naïve and 14 were treatment experienced. 33 patients initiated an IFN based regimen: 6 patients started IFN + RBV, 26 patients started Peg-IFN + RBV, none started Peg-IFN + RBV + DAA and 1 patient received other treatment. Among the treated cohort, demographic and disease characteristics were the following: the mean age was 54.5 years; 14 patients were male. 14 had minimal or no fibrosis, 2 portal fibrosis, 3 bridging fibrosis and 6 patients suffered from cirrhosis. HCV Genotype distribution was as follows: genotype 1: 11; genotype 2: 19 and genotype 3: 3. Table 1 describes the results at baseline and changes over 4, 12 and 48 weeks and end-of-treatment (EOT) for the quality of life and work productivity outcome measures (EQ-5D-5L, HCV-PRO and WPAI). Conclusions: Results from the Korean cohort of the MOSAIC study show a moderate trend for deterioration of health-related quality of life and work productivity associated with IFN based treatment for patients with chronic HCV infection during treatment period. Acknowledgements: The design, study conduct, analysis, and financial support of MOSAIC study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the content of the abstract. All authors had access to all relevant data and participated in writing, review, and approval of this abstract. Medical writing support was provided by Olivier Van de Steen of Medeor-consulting, funded by AbbVie. Disclosures: Sang Hoon Ahn: served as an advisor and lecturer for Bristol-Myers Squibb, Gilead Sciences, F.Hoffmann-La Roche, Merck, AbbVie, and has received unrestricted grants from Bristol-Myers Squibb, Gilead Sciences, and F. Hoffmann-La Roche for investigator- initiated trials Won Hyeok Choe: Nothing to disclosure Yoon Jun Kim: Nothing to disclosure Jeong Heo: received a grant from GSK; Research support from BMS, and Roche; Advisor for Abbvie, BMS, Gilead Sciences, Pharma Essentia, SillaJen, and Johnson & Johnson. Dorota Latarska-Smuga, Jiho Kang: are employees of AbbVie, Inc. and may hold stock or stock options. Seung Woon Paik: received grant and research support from AbbVie, BMS, Gilead, GSK, Merck, Novartis, and Roche

Electrodeposited Ni dendrites with high activity and durability for hydrogen evolution reaction in alkaline water electrolysis

Ahn, Sang Hyun,Hwang, Seung Jun,Yoo, Sung Jong,Choi, Insoo,Kim, Hyoung-Juhn,Jang, Jong Hyun,Nam, Suk Woo,Lim, Tae-Hoon,Lim, Taeho,Kim, Soo-Kil,Kim, Jae Jeong The Royal Society of Chemistry 2012 Journal of materials chemistry Vol.22 No.30

<P>Different shapes of various nickel structures, including dendrite, particle and film are fabricated by electrodeposition under various conditions. The shape of nickel structures is definitely dependent on the deposition potential, leading to different electrochemical surface area and edge facets. The nickel particle which has a polycrystalline center and edge is obtained at high negative potential. On the other hand, the nickel dendrite deposited by relatively low negative potential exhibits large electrochemical surface area and a particularly active facet for hydrogen evolution reaction (HER) in alkaline water electrolysis. In fact the nickel dendrite shows the highest catalytic activity and stability for HER among the various nickel structures.</P> <P>Graphic Abstract</P><P>Electrodeposited Ni dendrite catalysts have superior activity towards hydrogen evolution due both to the geometric and crystalline effects. <IMG SRC='http://pubs.rsc.org/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/image/GA?id=c2jm31439h'> </P>

Is an Articulating Device Beneficial to Perform D2 Lymphadectomy?

Sang-Hoon Ahn 대한외과학회 2022 대한외과학회 학술대회 초록집 Vol.2022 No.11

In vitro and in vivo pharmacokinetic characterization of LMT-28 as a novel small molecular interleukin-6 inhibitor

Ahn, Sung-Hoon,Heo, Tae-Hwe,Jun, Hyun-Sik,Choi, Yongseok Asian Australasian Association of Animal Productio 2020 Animal Bioscience Vol.33 No.4

Objective: Interleukin-6 (IL-6) is a T cell-derived B cell stimulating factor which plays an important role in inflammatory diseases. In this study, the pharmacokinetic properties of LMT-28 including physicochemical property, in vitro liver microsomal stability and an in vivo pharmacokinetic study using BALB/c mice were characterized. Methods: LMT-28 has been synthesized and is being developed as a novel therapeutic IL-6 inhibitor. The physicochemical properties and in vitro pharmacokinetic profiles such as liver microsomal stability and Madin-Darby canine kidney (MDCK) cell permeability assay were examined. For in vivo pharmacokinetic studies, pharmacokinetic parameters using BALB/c mice were calculated. Results: The logarithm of the partition coefficient value (LogP; 3.65) and the apparent permeability coefficient values (P_app; 9.7×10^-6 cm/s) showed that LMT-28 possesses a moderate-high cell permeability property across MDCK cell monolayers. The plasma protein binding rate of LMT-28 was 92.4% and mostly bound to serum albumin. The metabolic half-life (t_1/2) values of LMT-28 were 15.3 min for rat and 21.9 min for human at the concentration 1 μM. The area under the plasma drug concentration-time curve and C_max after oral administration (5 mg/kg) of LMT-28 were 302±209 h·ng/mL and 137±100 ng/mL, respectively. Conclusion: These data suggest that LMT-28 may have good physicochemical and pharmacokinetic properties and may be a novel oral drug candidate as the first synthetic IL-6 inhibitor to ameliorate mammalian inflammation.

Efficiency improvement of dye-sensitized solar cells using graft copolymer-templated mesoporous TiO₂ films as an interfacial layer

Ahn, Sung Hoon,Jeon, Harim,Son, Kyung Jin,Ahn, Hyungju,Koh, Won-Gun,Ryu, Du Yeol,Kim, Jong Hak Royal Society of Chemistry 2011 Journal of materials chemistry Vol.21 No.6

<P>Organized mesoporous TiO<SUB>2</SUB> films with high porosity and good connectivity were synthesized <I>via</I> sol–gel by templating an amphiphilic graft copolymer consisting of poly(vinyl chloride) backbone and poly(oxyethylene methacrylate) side chains, <I>i.e.</I>, PVC-<I>g</I>-POEM. The randomly microphase-separated graft copolymer was self-reorganized to exhibit a well-ordered micellar morphology upon controlling polymer–solvent interactions, as confirmed by atomic force microscope (AFM) and glazing incidence small-angle X-ray scattering (GISAXS). These organized mesoporous TiO<SUB>2</SUB> films, 550 nm in thickness, were used an an interfacial layer between a nanocrystalline TiO<SUB>2</SUB> thick layer and a conducting glass in dye-sensitized solar cells (DSSC). Introduction of the organized mesoporous TiO<SUB>2</SUB> layer resulted in the increased transmittance of visible light, decreased interfacial resistance and enhanced electron lifetime. As a result, an energy conversion efficiency of DSSC employing polymer electrolyte was significantly improved from 3.5% to 5.0% at 100 mW cm<SUP>−2</SUP>.</P> <P>Graphic Abstract</P><P>Organized mesoporous TiO<SUB>2</SUB> films synthesized <I>via</I> sol–gel by templating an amphiphilic graft copolymer exhibited increased transmittance, decreased interfacial resistance and enhanced electron lifetime, leading to performance improvement of dye-sensitized solar cells. <IMG SRC='http://pubs.rsc.org/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/image/GA?id=c0jm02706e'> </P>

Dirac electrons in a dodecagonal graphene quasicrystal

Ahn, Sung Joon,Moon, Pilkyung,Kim, Tae-Hoon,Kim, Hyun-Woo,Shin, Ha-Chul,Kim, Eun Hye,Cha, Hyun Woo,Kahng, Se-Jong,Kim, Philip,Koshino, Mikito,Son, Young-Woo,Yang, Cheol-Woong,Ahn, Joung Real American Association for the Advancement of Scienc 2018 Science Vol.361 No.6404

<P>Quantum states of quasiparticles in solids are dictated by symmetry. We have experimentally demonstrated quantum states of Dirac electrons in a two-dimensional quasicrystal without translational symmetry. A dodecagonal quasicrystalline order was realized by epitaxial growth of twisted bilayer graphene rotated exactly 30 degrees. We grew the graphene quasicrystal up to a millimeter scale on a silicon carbide surface while maintaining the single rotation angle over an entire sample and successfully isolated the quasicrystal from a substrate, demonstrating its structural and chemical stability under ambient conditions. Multiple Dirac cones replicated with the 12-fold rotational symmetry were observed in angle-resolved photoemission spectra, which revealed anomalous strong interlayer coupling with quasi-periodicity. Our study provides a way to explore physical properties of relativistic fermions with controllable quasicrystalline orders.</P>

Safety and Efficacy of Besifovir in Treatment-Naive Chronic Hepatitis B Virus Infection: A Randomized, Double-Blind, Double Dummy, Phase 3 Study

( Sang Hoon Ahn ),( Won Kim ),( Young Kul Jung ),( Jin Mo Yang ),( Jae Young Jang ),( Yong Oh Kweon ),( Yong Kyun Cho ),( Yoon Jun Kim ),( Gun Young Hong ),( Dong Joon Kim ),( Soon Ho Um ),( Joo Hyun 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1

Aims: Besifovir is an acyclic nucleotide phosphonate known to be effective in hepatitis B virus (HBV) DNA suppression for both treatment- naïve and lamivudine-resistant chronic HBV infection in preliminary studies. We assessed the safety and efficacy of besifovir comparing with tenofovir in treatment-naïve chronic hepatitis B patients. Methods: A total of 187 patients were randomly received besifovir dipivoxil 150mg or tenofovir disoproxil fumarate 300mg. Eligible subjects were patients with chronic HBV infection. We measured the proportion of patients who had HBV DNA less than 69 IU/mL at week 48 as the primary efficacy endpoint. Key secondary endpoints were histological response (i.e., a reduction in the Knodell necroinflammation score of 2 or more points without worsening fibrosis), serum HBV DNA reduction, and liver function tests. Also, bone mineral density (BMD) and renal parameters were evaluated. Results: The proportion of patients who achieved primary endpoint of HBV DNA (< 69 IU/mL) at week 48 were 85.33% and 88.75% among those who received besifovir and tenofovir, respectively. Besifovir was shown to be non-inferior to tenofovir (lower limit of 95% CI for the treatment difference =-0.14). Histological improvement of 29 patients who underwent liver biopsy was evaluated, and we found that significantly more patients treated with besifovir had improved histological response than those treated with tenofovir (77.78% vs. 36.36%, p=0.0482). There was no difference in intrahepatic cccDNA reduction between the two groups (p=0.35). None of the patients had resistant to mutations or increase in serum creatinine >0.5mg/dL from baseline. Patients who received besifovir had smaller decrease in BMD during 48 weeks than that of tenofovir (besifovir -0.02±0.44, tenofovir -0.10±0.86, p=0.0248). There was no adverse drug reaction leading the patients to withdrawal. Conclusions: This phase 3 study demonstrated that besifovir had comparable efficacy and safety profile to tenofovir in the treatment of treatment-naïve chronic hepatitis B patients. Besifovir showed better profile than tenofovir in both histological response and bone loss. An open-label extension study is ongoing with besifovir to investigate long-term efficacy and safety.

Predictors of recurrent acute myocardial infarction despite successful percutaneous coronary intervention

Sang Hun Lee,Myung Ho Jeong,Joon Ho Ahn,Dae Young Hyun,Kyung Hoon Cho,Min Chul Kim,Doo Sun Sim,Young Joon Hong,Ju Han Kim,Youngkeun Ahn,Jin Yong Hwang,Weon Kim,Jong Seon Park,Chang-Hwan Yoon,Seung Ho 대한내과학회 2022 The Korean Journal of Internal Medicine Vol.37 No.4

Background/Aims: Recurrent acute myocardial infarction (AMI) is an adverse cardiac event in patients with a first AMI. The predictors of recurrent AMI after the first AMI in patients who underwent successful percutaneous coronary intervention (PCI) have not been elucidated. Methods: We analyzed the data collected from 9,869 patients (63.2 ± 12.4 years, men:women = 7,446:2,423) who were enrolled in the Korea Acute Myocardial Infarction Registry-National Institute of Health between November 2011 and October 2015, had suffered their first AMI and had received successful PCI during the index hospitalization. Multivariable logistic regression analysis was performed to identify the independent predictors of recurrent AMI following the first AMI. Results: The cumulative incidence of recurrent AMI after successful PCI was 3.6% (359/9,869). According to the multivariable logistic regression analysis, the significant predictive factors for recurrent AMI were diabetes mellitus, renal dysfunction, atypical chest pain, and multivessel disease. Conclusions: In this Korean prospective cohort study, the independent predictors of recurrent AMI after successful PCI for the first AMI were diabetes mellitus, renal dysfunction, atypical chest pain, and multivessel disease.

A Phase 3 Study of TAF Compared with TDF in Patients with HBeAg-Negative CHB: Week48 Efficacy Results of Korea Patients

( Sang Hoon Ahn ),( Young-Suk Lim ),( Si-Hyun Bae ),( Hyung Joon Kim ),( Kwan Sik Lee ),( Won Young Tak ),( Byoung Kuk Jang ),( Ki Tae Yoon ),( Seung Woon Paik ),( Kwan Soo Byun ),( Sunjin Hwang ),( B 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1

Aims: In this Phase-3 randomized, double-blind, active-controlled study in 425 HBeAg-negative patients, the efficacy of TAF was demonstrated to be non-inferior to that of TDF at Week48 in the proportion with HBV DNA<29 IU/mL with improved bone and renal effects. Here we present the subgroup efficacy analysis of Korea patients in the study. Methods: Patients with HBeAg-negative CHB were randomized 2:1 to TAF 25mg or TDF 300mg, and treated for 96weeks. The primary efficacy analysis was the proportion with HBV DNA<29 IU/mL at Week48. The results for the subgroup of Korean patients were compared to non-Koreans. Results: Of the 425 patients who were randomized and treated, 45 subjects (11%; TAF 30; TDF 15 subjects) were enrolled in Korea. In contrast to the non-Korea population, the Korea population for the TAF and TDF groups included a higher proportion of females (60% and 47%) a lower mean baseline HBV DNA level, and more treatment experienced subjects. Nearly all were genotype C. Key efficacy end points are summarized in the Table. The percentages of Korean subjects with HBV DNA levels<29 IU/mL at Week48 were 100.0% with TAF and 80.0% with TDF. The results were consistent with the non-Korean and overall populations. A greater percentage of patients treated with TAF also achieved normalization of serum ALT values. The rates of treatment discontinuations and serious AEs were low and similar in the two arms. No viral resistance was observed overall. Similar to non-Korean subjects, those from Korea who were treated with TAF also showed smaller declines in BMD at hip and spine and in CrCl at Week48 compared with TDF subjects in Korea. Conclusions: Compared to TDF 300mg, the efficacy and safety of TAF 25mg in patients with HBeAg-negative CHB from Korea were consistent with those of the nonKorea and overall populations at Week48.

Characterization of Naturally Occurring Hepatitis B Virus Mutants in the Precore Region

( Sang Hoon Ahn ),( Hye Young Chang ),( Myung Eun Lee ),( Yong Wook Choi ),( Kwang Hyub Han ) 대한간학회 2006 Clinical and Molecular Hepatology(대한간학회지) Vol.12 No.3(S)